ArticleBMC neurology2026
Clinical features and outcomes of anti-NMDAR autoimmune-related central nervous system involvement in patients with teratoma: a retrospective cohort study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTeratoma-associated anti-NMDAR encephalitis represents a rare but clinically severe subset of autoimmune encephalitis. Evidence regarding predictors of disease severity and 12-month functional outcomes remains limited.
methodsIn this single-center retrospective cohort study, 84 patients who met the inclusion criteria for teratoma-associated anti-NMDAR encephalitis were included for analysis. Clinical manifestations, MRI and EEG findings, treatment characteristics, and tumor-related markers (Ki-67, AFP, LDH) were systematically collected. Severe disease was defined as requiring ICU care with organ support, mechanical ventilation, or documented central hypoventilation. Functional outcomes were evaluated using the modified Rankin Scale (mRS) at 6 and 12 months. Univariable and multivariable logistic regression models were used to identify independent predictors of poor 12-month outcomes (mRS > 2). ROC analyses assessed discriminatory performance.
resultsCentral hypoventilation (57.14% vs. 10.71%), multifocal MRI lesions (25.00% vs. 7.14%), extreme delta-brush on EEG (42.86% vs. 12.50%), and higher symptom burden were significantly associated with severe disease (all P < 0.05). At 12 months, 23.81% of patients had poor functional outcomes. Independent predictors of poor outcome included central hypoventilation (adjusted OR 5.86, 95% CI 2.01–17.10), ≥ 4 symptom categories (adjusted OR 3.42, 95% CI 1.15–10.20), multifocal MRI involvement (adjusted OR 3.71, 95% CI 1.02–13.40), extreme delta-brush (adjusted OR 4.28, 95% CI 1.31–13.90), and tumor resection > 21 days after onset (adjusted OR 3.16, 95% CI 1.05–9.53). The multivariable model achieved strong predictive performance (AUC 0.89).
conclusionsMarkers of diffuse neuroinvolvement—including central hypoventilation, higher symptom burden, multifocal MRI lesions, and extreme delta-brush—are key indicators of severe disease and poor long-term outcomes in pediatric teratoma-associated anti-NMDAR encephalitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.